What is Eli Lilly's mirikizumab approved for in China?

Eli Lilly's mirikizumab is approved in China for the treatment of moderately to severely active Crohn's disease and ulcerative colitis.

Is mirikizumab a new drug for Eli Lilly in China?

Mirikizumab is the first innovative medicine in the digestive immunity field approved for Eli Lilly's China branch, though the drug is already approved in other countries like the U.S.

What is the market outlook for ulcerative colitis therapy in China?

The ulcerative colitis therapy market in China is expected to experience considerable growth over the next decade, driven by the introduction of targeted medicines like mirikizumab.

Home / Health / Eli Lilly Drug Gets China Nod for Gut Disease

Eli Lilly Drug Gets China Nod for Gut Disease

11 Feb

•

Summary

Eli Lilly's mirikizumab is now approved in China.
The drug treats Crohn's disease and ulcerative colitis.
This marks a significant expansion for the treatment.

Eli Lilly Drug Gets China Nod for Gut Disease

Eli Lilly's drug mirikizumab has secured approval from Chinese regulators for treating chronic inflammatory bowel diseases. This development grants the U.S. pharmaceutical company access to China's substantial pharmaceutical market.

The approved indications include moderately to severely active Crohn's disease and ulcerative colitis. This is the first innovative medicine approval for Eli Lilly's China branch in the digestive immunity sector. Mirikizumab has previously received approval in other key markets, including the United States.

Market analysts predict significant growth in China's ulcerative colitis therapy market over the next decade. This growth is anticipated to be propelled by the introduction and adoption of targeted treatments such as Eli Lilly's newly approved drug.